Last updated: 16 November 2026
Reviewed by: David Small BSc (Hons), MSc, MTOPRA (Founder & CEO)
What Is Medical Device Clinical Evaluation?
Clinical evaluation is the systematic and continuous process of collecting, appraising and analysing clinical data to demonstrate that a medical device is safe, achieves its intended clinical performance and maintains an acceptable benefit-risk profile when used as intended. Under the European Medical Device Regulation (EU MDR) 2017/745, clinical evaluation is not a one-off activity performed solely to obtain CE marking; it must be planned, conducted and updated throughout the device’s lifecycle.
Manufacturers placing medical devices on the European market must generate sufficient clinical evidence to demonstrate conformity with the relevant General Safety and Performance Requirements (GSPRs). The depth of clinical evaluation depends on factors such as the device’s classification, intended purpose, novelty, clinical claims and associated risks. Clinical evidence may be drawn from published scientific literature, existing clinical investigations and post-market clinical experience. Where the available evidence is insufficient, additional clinical investigations may be necessary, subject to the specific requirements of Article 61 of the EU MDR.
Clinical evaluation is closely integrated with risk management, technical documentation, quality management and post-market surveillance. Together, these activities help demonstrate that a device performs as intended and that its benefits continue to outweigh its risks throughout its lifecycle.
This guide explains every stage of the clinical evaluation process, from planning and identifying relevant clinical evidence through to preparing a Clinical Evaluation Report (CER), maintaining compliance through Post-Market Clinical Follow-up (PMCF) and updating clinical evidence using Post-Market Surveillance (PMS). Whether you are developing a new device or maintaining an existing CE-marked product, understanding clinical evaluation is essential for achieving and maintaining regulatory compliance under the EU MDR.
New to the EU MDR?
If you're looking for a complete introduction to Regulation (EU) 2017/745, including device classification, General Safety and Performance Requirements (GSPRs), Clinical Evaluation, Technical Documentation, Risk Management, Notified Body requirements and CE marking, explore our EU MDR for Beginners: A Comprehensive Guide.
Why Clinical Evaluation Is Essential Under the EU MDR
Clinical evaluation is far more than a regulatory documentation exercise. It is the process through which manufacturers demonstrate that a medical device achieves its intended clinical performance, meets applicable safety requirements and provides an acceptable benefit-risk profile. Rather than relying solely on laboratory testing or bench performance, manufacturers must assess sufficient clinical evidence to demonstrate conformity with the relevant General Safety and Performance Requirements (GSPRs).
Under Article 61 and Annex XIV of the EU MDR, manufacturers must plan, conduct, document and continuously update clinical evaluations for their medical devices, regardless of classification. The nature and extent of the clinical evidence required must be appropriate to the device’s intended purpose, classification, characteristics and associated risks. Clinical evaluation supports conformity assessment, benefit-risk analysis, labelling, clinical claims, risk management, Post-Market Surveillance (PMS) and Post-Market Clinical Follow-up (PMCF), where applicable.
A robust clinical evaluation also supports wider business objectives by helping manufacturers:
-
Demonstrate conformity with the relevant EU MDR requirements.
-
Support CE marking and ongoing market access.
-
Substantiate clinical and marketing claims with objective evidence.
-
Demonstrate that the benefits of the device outweigh its associated risks.
-
Identify evidence gaps requiring additional clinical data.
-
Support risk management in accordance with ISO 14971.
-
Strengthen technical documentation for conformity assessment and Notified Body review, where applicable.
-
Continuously monitor device safety and clinical performance throughout its lifecycle.
Ultimately, clinical evaluation provides an essential scientific and clinical foundation for demonstrating the safety, performance and regulatory compliance of medical devices throughout their lifecycle.
How Clinical Evaluation Fits into EU MDR Compliance
Clinical evaluation does not exist in isolation. It forms an essential component of the technical documentation required under the EU Medical Device Regulation (EU MDR) 2017/745. The findings and conclusions of a clinical evaluation inform other areas of regulatory compliance, while information generated through the manufacturer’s Quality Management System (QMS) feeds back into the ongoing clinical evaluation process.
For example, the device’s intended purpose defines the clinical questions that must be addressed during the evaluation. Risk management, conducted in accordance with ISO 14971, identifies hazards and residual risks that must be considered when assessing the device’s clinical safety and benefit-risk profile. Biological evaluation contributes to assessing the biological safety of patient-contacting materials, while usability engineering helps assess risks associated with device use by its intended users.
Once a device is placed on the market, Post-Market Surveillance (PMS) provides information about its real-world safety and performance. Post-Market Clinical Follow-up (PMCF), where applicable, further supports the ongoing collection and evaluation of clinical data. Relevant findings from these activities must be considered when reviewing and updating the Clinical Evaluation Report (CER).
This continuous exchange of information helps manufacturers maintain an accurate understanding of their device’s safety, clinical performance and benefit-risk profile throughout its lifecycle. Rather than treating regulatory documents as independent exercises, manufacturers should maintain an integrated technical documentation system in which clinical evaluation both informs and draws upon other compliance activities.
Clinical Evaluation's Relationship with Other MDR Requirements
|
Regulatory Activity |
Relationship to Clinical Evaluation |
|---|---|
|
Intended Purpose |
Defines the clinical claims, intended clinical benefits and performance characteristics that must be supported by clinical evidence. |
|
General Safety and Performance Requirements (GSPRs) |
Clinical evidence supports demonstration of conformity with the relevant safety and performance requirements. |
|
Risk Management (ISO 14971) |
Clinical data informs the assessment of residual risks and the overall benefit-risk profile of the device. |
|
Biological Evaluation (ISO 10993) |
Provides supporting biological safety evidence that informs the overall clinical safety assessment. |
|
Clinical Investigation |
Generates clinical evidence where required under Article 61 or where existing evidence is insufficient to demonstrate conformity. |
|
Technical Documentation |
The Clinical Evaluation Report forms an essential component of the technical documentation required under Annexes II and III of the EU MDR. |
|
Post-Market Surveillance (PMS) |
Collects and analyses post-market information relevant to the device’s continued safety, performance and benefit-risk profile. |
|
Post-Market Clinical Follow-up (PMCF) |
Proactively collects and evaluates clinical data after market placement to confirm safety and performance and address residual uncertainties, where applicable. |
|
Clinical Evaluation Report (CER) |
Documents the methodology, clinical evidence, appraisal, analysis and conclusions of the clinical evaluation process. |
Why This Integration Matters
Manufacturers sometimes view clinical evaluation as a standalone document prepared shortly before CE marking. In reality, it is a continuous process that draws upon information generated throughout the medical device lifecycle. Changes to the intended purpose, device design, manufacturing processes, risk profile, available clinical evidence or post-market performance may trigger the need to review and update the Clinical Evaluation Report (CER).
This integrated approach helps ensure that regulatory decisions are based on current clinical evidence rather than historical assumptions. By maintaining alignment between clinical evaluation, risk management, technical documentation and post-market surveillance, manufacturers can support ongoing EU MDR compliance and demonstrate that their devices remain safe, achieve their intended clinical performance and maintain an acceptable benefit-risk profile throughout their lifecycle.
The Medical Device Clinical Evaluation Process
The medical device clinical evaluation process follows a structured, evidence-based methodology designed to demonstrate that a device meets its intended clinical performance, safety and benefit-risk requirements. Under Annex XIV Part A of the EU MDR, manufacturers must systematically plan, identify, appraise and analyse relevant clinical data to establish whether sufficient clinical evidence exists to demonstrate conformity with the applicable General Safety and Performance Requirements (GSPRs).
The process begins with a Clinical Evaluation Plan (CEP), which defines the scope, objectives, methodology and clinical evidence requirements for the evaluation. Manufacturers must then identify and critically appraise relevant clinical data, including scientific literature, clinical investigations and available post-market information, before analysing the evidence and documenting their conclusions in a Clinical Evaluation Report (CER).
Clinical evaluation must be maintained throughout the device lifecycle. New information obtained through Post-Market Surveillance (PMS), Post-Market Clinical Follow-up (PMCF), scientific publications or clinical investigations must be considered when reviewing and updating the evaluation.
Although the extent and nature of clinical evidence required will vary according to device classification, intended purpose, characteristics and associated risks, the evaluation must follow a systematic, objective and appropriately documented methodology.
The Seven Stages of Clinical Evaluation
1. Develop a Clinical Evaluation Plan (CEP)
The clinical evaluation process begins with a Clinical Evaluation Plan (CEP), which establishes the objectives, scope and methodology of the evaluation. Under Annex XIV Part A of the EU MDR, the CEP must identify the device’s intended purpose, target patient groups, intended clinical benefits, relevant General Safety and Performance Requirements (GSPRs) and the clinical evidence required to demonstrate conformity.
The plan should define the methods used to identify, appraise and analyse clinical data, including scientific literature, clinical investigations and relevant post-market information. It should also address clinical safety, intended clinical performance, benefit-risk acceptability, relevant clinical outcome parameters and the approach to updating the evaluation throughout the device lifecycle.
A well-structured Clinical Evaluation Plan provides a consistent, transparent and reproducible framework for conducting the evaluation and identifying any gaps in the available clinical evidence.
2. Identify Relevant Clinical Evidence
Manufacturers must systematically identify available clinical data relevant to the device’s intended purpose, clinical performance, safety and benefit-risk profile. Under Annex XIV Part A of the EU MDR, this involves identifying both favourable and unfavourable evidence through a documented and reproducible search strategy.
Relevant sources of clinical evidence may include:
-
Published scientific and clinical literature.
-
Clinical investigations involving the device under evaluation.
-
Clinical data from equivalent devices, where equivalence can be adequately demonstrated in accordance with EU MDR requirements.
-
Post-Market Surveillance (PMS) data.
-
Post-Market Clinical Follow-up (PMCF) studies and findings.
-
Device registries and relevant real-world clinical data.
-
Complaint, vigilance and adverse event data.
Literature searches should use appropriate scientific databases, clearly defined search terms and documented inclusion and exclusion criteria. Manufacturers must ensure that relevant evidence is identified objectively, including data that may challenge existing assumptions about device safety or clinical performance.
The objective is to establish a comprehensive and traceable body of clinical evidence that can subsequently be critically appraised and analysed to determine whether it is sufficient to demonstrate conformity with the applicable General Safety and Performance Requirements (GSPRs).
3. Critically Appraise the Evidence
Not all clinical evidence carries equal weight. Each clinical study, scientific publication or dataset must be critically appraised to determine its scientific validity, relevance, reliability and contribution to demonstrating the device’s safety and clinical performance.
Under Annex XIV Part A of the EU MDR, manufacturers should assess factors such as:
-
Study design and methodology: Whether the research methods are appropriate and scientifically robust.
-
Patient population: Whether the study participants are representative of the device’s intended patient population.
-
Clinical relevance: Whether the evidence relates to the device’s intended purpose, clinical claims and performance characteristics.
-
Data quality and reliability: Whether the findings are supported by sufficient, reliable and appropriately documented data.
-
Risk of bias: Whether methodological limitations, conflicts of interest or other factors could influence the findings.
-
Equivalence: Where data from another device is used, whether the required technical, biological and clinical equivalence can be demonstrated.
Manufacturers should document their appraisal methodology and justify the weighting assigned to individual studies and datasets. Evidence with significant limitations should be appropriately weighted or excluded with justification, ensuring that conclusions are based on a balanced and scientifically defensible assessment of the available clinical data.
4. Analyse the Clinical Data
Following critical appraisal, the available clinical evidence must be analysed collectively to determine whether the medical device achieves its intended clinical performance, meets the relevant safety requirements and maintains an acceptable benefit-risk profile.
Under Annex XIV Part A of the EU MDR, this analysis should consider:
-
Clinical performance: Whether the available evidence demonstrates that the device achieves its intended clinical benefits and performance claims.
-
Clinical safety: Whether identified adverse events, side effects and clinical risks are adequately characterised and acceptable.
-
Benefit-risk assessment: Whether the demonstrated clinical benefits outweigh the associated risks when the device is used as intended.
-
Consistency of evidence: Whether findings from different studies, clinical investigations and post-market data support consistent conclusions.
-
Evidence gaps and uncertainties: Whether limitations in the available clinical data require additional investigations, further analysis or Post-Market Clinical Follow-up (PMCF).
The conclusions should be evaluated alongside the device’s Risk Management File, Biological Evaluation and other relevant technical documentation to ensure consistency between the clinical evidence, identified risks and claimed clinical benefits.
Where evidence gaps remain, manufacturers must determine whether additional clinical data is necessary to demonstrate conformity with the applicable General Safety and Performance Requirements (GSPRs).
5. Identify Evidence Gaps
Where the available clinical evidence is insufficient to demonstrate the device’s safety, intended clinical performance or an acceptable benefit-risk profile, manufacturers must identify the evidence gaps and determine how they will be addressed.
Depending on the nature and significance of the gaps, this may involve:
-
Additional literature reviews: Identifying further relevant clinical data or addressing limitations in the existing evidence.
-
Further clinical investigations: Generating additional clinical evidence where required under Article 61 or necessary to demonstrate conformity.
-
Additional analysis: Reassessing existing clinical data, clinical claims or risk management conclusions where appropriate.
-
Post-Market Clinical Follow-up (PMCF): Addressing residual clinical uncertainties and confirming continued safety and performance after market placement, where sufficient evidence already exists to support conformity.
Evidence gaps that prevent demonstration of conformity with the applicable General Safety and Performance Requirements (GSPRs) must be adequately addressed before the device is placed on the market. PMCF should not be used as a substitute for essential pre-market clinical evidence.
Identifying and addressing evidence gaps early helps manufacturers establish a robust clinical evaluation strategy, reduce the risk of delays during Notified Body assessment, where applicable, and maintain regulatory compliance throughout the device lifecycle.
6. Prepare the Clinical Evaluation Report (CER)
The findings and conclusions of the clinical evaluation must be documented in a Clinical Evaluation Report (CER). Under Annex XIV Part A of the EU MDR, the CER provides a structured, scientifically justified assessment of the available clinical evidence and demonstrates whether the device meets the relevant safety, clinical performance and benefit-risk requirements.
A comprehensive Clinical Evaluation Report should document:
-
Evaluation methodology: The approach defined in the Clinical Evaluation Plan (CEP), including the methods used to identify, appraise and analyse clinical data.
-
Clinical evidence: The scientific literature, clinical investigations and relevant post-market data considered during the evaluation.
-
Critical appraisal: The assessment of the quality, relevance and reliability of the available clinical evidence.
-
Clinical analysis: The evaluation of the device’s safety, intended clinical performance and benefit-risk profile.
-
Evidence gaps: Any remaining limitations, uncertainties or requirements for additional clinical evidence.
-
Conclusions: A scientifically justified determination of whether sufficient clinical evidence supports conformity with the applicable General Safety and Performance Requirements (GSPRs).
The Clinical Evaluation Report forms an essential component of the manufacturer’s technical documentation under the EU MDR and must be maintained and updated as relevant new clinical evidence becomes available. Where Notified Body involvement is required, the CER is subject to review as part of the applicable conformity assessment process.
7. Maintain the Clinical Evaluation Throughout the Device Lifecycle
Clinical evaluation does not end once a medical device has obtained CE marking. Under Article 61 and Annex XIV of the EU MDR, manufacturers must continuously review relevant clinical information throughout the device lifecycle to ensure that the Clinical Evaluation Report (CER) remains current and continues to support the device’s safety, clinical performance and benefit-risk profile.
Relevant information may include:
-
Post-Market Surveillance (PMS): New information concerning device safety, performance, complaints and real-world experience.
-
Post-Market Clinical Follow-up (PMCF): Clinical data collected to confirm continued safety and performance and address residual uncertainties, where applicable.
-
Vigilance activities: Reports of serious incidents, field safety corrective actions and emerging safety concerns.
-
Scientific literature: New clinical studies, publications or developments in the current state of the art.
-
Device changes: Modifications to the intended purpose, design, clinical claims or risk profile that may affect the existing clinical evidence.
Manufacturers should establish documented procedures for periodically reviewing their clinical evaluation and identifying when updates are necessary. Significant new clinical findings, emerging risks or changes affecting the device’s safety or performance may require the CER to be updated.
The frequency and extent of updates should reflect the device’s risk classification, available clinical evidence, post-market findings and applicable regulatory requirements. This ensures that the clinical evaluation remains scientifically justified and continues to support conformity with the EU MDR throughout the device lifecycle.
What Counts as Clinical Evidence?
Clinical evaluation is only as strong as the evidence on which it is based. Under the EU MDR, manufacturers must systematically identify, appraise and analyse relevant clinical data to demonstrate that their medical device achieves its intended clinical performance, meets applicable safety requirements and maintains an acceptable benefit-risk profile.
The EU MDR distinguishes between clinical data and clinical evidence. Under Article 2(48), clinical data refers to information concerning the safety or performance of a device generated from its clinical use. Clinical evidence, defined under Article 2(51), comprises clinical data and clinical evaluation results of sufficient amount and quality to support a qualified assessment of whether the device is safe and achieves its intended clinical benefits when used as intended.
The MDR does not prescribe a single source of clinical evidence for every device. Instead, manufacturers must consider relevant information appropriate to the device’s intended purpose, classification, novelty, clinical risks and available clinical experience. Higher-risk or novel technologies may require more extensive clinical evidence, including clinical investigations, while established technologies may be supported by existing clinical data where the applicable regulatory requirements are satisfied.
Importantly, clinical evidence must be evaluated objectively rather than selected to support a predetermined conclusion. Manufacturers should consider both favourable and unfavourable findings, including contradictory results, limitations and uncertainties, to ensure that the Clinical Evaluation Report (CER) presents a balanced and scientifically justified assessment of the available evidence.
Common Sources of Clinical Evidence
Manufacturers may draw upon several sources of clinical data when conducting a clinical evaluation. The relevance and suitability of each source must be assessed in relation to the device’s intended purpose, clinical claims and applicable EU MDR requirements.
|
Clinical Evidence Source |
Purpose and Relevance to Clinical Evaluation |
|---|---|
|
Scientific Literature |
Published clinical studies, systematic reviews and peer-reviewed research providing relevant information on device safety, clinical performance and the current state of the art. |
|
Clinical Investigations |
Clinical studies conducted to assess device safety or performance and generate clinical data supporting conformity with EU MDR requirements. |
|
Equivalent Devices |
Clinical data from another device where technical, biological and clinical equivalence can be demonstrated in accordance with the EU MDR. |
|
Post-Market Surveillance (PMS) |
Information collected after market placement, including relevant clinical experience, complaints and safety trends, used to assess continued safety and performance. |
|
Post-Market Clinical Follow-up (PMCF) |
Proactive collection and evaluation of clinical data to confirm continued safety, clinical performance and benefit-risk acceptability and identify emerging risks. |
|
Registries and Real-World Evidence |
Relevant clinical information obtained from patient registries, healthcare databases and routine clinical practice. |
|
Vigilance Data |
Reports of serious incidents, Field Safety Corrective Actions (FSCAs) and relevant safety trends that inform the assessment of device-related risks. |
|
Published Standards and Clinical Guidelines |
Recognised standards, clinical practice guidelines and professional recommendations that help establish the current state of the art and relevant clinical benchmarks. |
The Clinical Evaluation Plan (CEP)
Every clinical evaluation should be guided by a documented Clinical Evaluation Plan (CEP). Required under Annex XIV, Part A of the EU Medical Device Regulation (EU MDR), the CEP establishes the objectives, scope and methodology of the clinical evaluation. It defines how relevant clinical data will be identified, appraised and analysed to demonstrate conformity with applicable General Safety and Performance Requirements (GSPRs).
The Clinical Evaluation Plan provides a structured framework for assessing clinical evidence against the device’s intended purpose, clinical benefits, safety and performance claims. It supports a systematic, transparent and scientifically justified evaluation that can be reviewed by Notified Bodies where applicable. The CEP also establishes the methodology underpinning the Clinical Evaluation Report (CER), which documents the findings and conclusions of the evaluation. This provides traceability between the planned evaluation methodology, the clinical evidence assessed and the conclusions documented in the Clinical Evaluation Report.
Developing the CEP early in the regulatory process helps manufacturers identify potential gaps in clinical evidence and determine whether additional literature reviews, clinical investigations or other evidence-generation activities are necessary. It also establishes how the clinical evaluation will be updated throughout the device lifecycle, including consideration of relevant Post-Market Surveillance (PMS) and Post-Market Clinical Follow-up (PMCF) findings.
What Should a Clinical Evaluation Plan Include?
Under EU MDR Annex XIV, Part A, a Clinical Evaluation Plan (CEP) must address specific regulatory requirements. The level of detail and any additional information will depend on the device’s intended purpose, classification, complexity and associated clinical risks. A comprehensive CEP should address the following elements:
|
Clinical Evaluation Plan Element |
Purpose |
|---|---|
|
Device Description and Intended Purpose |
Defines the device, intended purpose, indications, target patient population, intended clinical benefits and relevant clinical claims. |
|
Applicable GSPRs |
Identifies the General Safety and Performance Requirements that require support from relevant clinical data. |
|
Clinical Benefits and Outcome Parameters |
Specifies the intended clinical benefits and the clinical outcome parameters used to assess them. |
|
Clinical Safety and Performance |
Defines the methods used to assess clinical safety and performance, including qualitative and quantitative aspects and any residual risks or side effects. |
|
Benefit-Risk Assessment |
Establishes the parameters used to determine whether the device’s benefit-risk ratio remains acceptable in light of the current state of the art. |
|
Evidence Sources |
Identifies relevant clinical data sources, including scientific literature, clinical investigations, equivalent devices where justified, PMS and PMCF. |
|
Literature Search Strategy |
Describes the databases, search terms, inclusion and exclusion criteria, and methods used to identify relevant scientific literature. |
|
Critical Appraisal Methodology |
Defines how the relevance, methodological quality, scientific validity and limitations of clinical data will be assessed. |
|
Clinical Data Analysis |
Explains how clinical evidence will be analysed and combined to assess clinical safety, performance, benefits and residual risks. |
|
Clinical Development Plan |
Outlines the planned progression of clinical evidence generation, from exploratory investigations where applicable through confirmatory investigations and PMCF, including relevant milestones and potential acceptance criteria. |
|
Clinical Evaluation Update Strategy |
Establishes how and when the clinical evaluation will be reviewed and updated using new clinical data, PMS findings and PMCF results. |
The Clinical Evaluation Report (CER)
The Clinical Evaluation Report (CER) documents the findings and conclusions of the clinical evaluation process. It brings together relevant clinical evidence, records the critical appraisal and analysis of available data, and presents the manufacturer’s conclusions regarding the device’s clinical safety, performance and benefit-risk profile.
Unlike the Clinical Evaluation Plan (CEP), which establishes how the evaluation will be conducted, the CER documents the methodology applied, the clinical evidence assessed and the conclusions reached. It forms an essential part of the medical device’s technical documentation and is subject to review by Notified Bodies where applicable during EU MDR conformity assessment.
A comprehensive CER must demonstrate whether the available clinical evidence is sufficient to support the device’s intended purpose, substantiate relevant clinical claims and demonstrate conformity with applicable General Safety and Performance Requirements (GSPRs). The report should provide a balanced assessment of favourable and unfavourable findings, including evidence limitations, uncertainties, residual risks and any identified clinical evidence gaps.
What Should a Clinical Evaluation Report Include?
The structure and level of detail of a Clinical Evaluation Report (CER) will depend on the device’s intended purpose, classification, complexity and associated clinical risks. In accordance with EU MDR Article 61 and Annex XIV, Part A, the report must document the clinical evaluation and its conclusions. A comprehensive CER will typically include the following sections:
|
Clinical Evaluation Report Section |
Purpose |
|---|---|
|
Executive Summary |
Summarises the clinical evaluation, principal findings, identified limitations and overall conclusions. |
|
Device Description and Intended Purpose |
Describes the device, intended purpose, indications, contraindications, target patient population, intended clinical benefits and relevant clinical claims. |
|
Regulatory Background |
Identifies the applicable EU MDR requirements, device classification, relevant GSPRs and regulatory standards or guidance. |
|
Clinical Evaluation Methodology |
Documents the methodology established in the Clinical Evaluation Plan (CEP), including evidence identification, selection, appraisal and analysis. |
|
Current State of the Art |
Reviews relevant clinical practice, alternative treatment options, recognised standards and clinical benchmarks against which the device is evaluated. |
|
Clinical Evidence Review |
Presents relevant clinical data from scientific literature, clinical investigations, equivalent devices where justified, PMS, PMCF and other applicable sources. |
|
Critical Appraisal |
Evaluates the scientific validity, methodological quality, relevance, reliability and limitations of the available clinical data. |
|
Clinical Data Analysis |
Analyses the totality of clinical evidence to assess clinical safety, performance, intended clinical benefits, residual risks and benefit-risk acceptability. |
|
Clinical Evidence Gaps and Limitations |
Identifies limitations, uncertainties, conflicting findings and any additional clinical evidence required to support regulatory conclusions. |
|
Conclusions and GSPR Conformity |
Determines whether sufficient clinical evidence supports the intended purpose, relevant clinical claims, acceptable benefit-risk profile and conformity with applicable GSPRs. |
|
References and Appendices |
Provides supporting literature, documented search strategies, appraisal records and other relevant evidence supporting the evaluation. |
Keeping the CER Up to Date
The Clinical Evaluation Report (CER) must be maintained throughout the medical device lifecycle. Under EU MDR Article 61 and Annex XIV, manufacturers must assess new clinical information and update the clinical evaluation where necessary to ensure its conclusions remain valid.
Circumstances that may trigger a CER review or update include:
-
New findings from Post-Market Surveillance (PMS) activities.
-
Results from Post-Market Clinical Follow-up (PMCF).
-
Newly published scientific literature or clinical investigation results.
-
Significant changes to the device’s design, intended purpose or clinical claims.
-
New or emerging risks identified through risk management activities.
-
Serious incidents, Field Safety Corrective Actions (FSCAs) or relevant vigilance trends.
-
Changes in the current state of the art that may affect clinical safety, performance or benefit-risk acceptability.
Manufacturers should establish a documented approach for reviewing new clinical information, assessing its impact and determining whether the CER requires updating. This helps ensure that clinical evaluation conclusions remain supported by current and sufficient clinical evidence.
Need to Prepare a Clinical Evaluation Report (CER)?
This guide introduces the role of the Clinical Evaluation Report within the EU MDR. If you need detailed guidance on CER structure, regulatory requirements, clinical evidence, benefit-risk assessment, literature reviews and Notified Body expectations, read our Clinical Evaluation Report: EU MDR Requirements.
Post-Market Clinical Follow-up (PMCF)
Clinical evaluation does not end when a medical device receives CE marking. Under the EU Medical Device Regulation (EU MDR), manufacturers must continue evaluating relevant clinical data throughout the device lifecycle to confirm that its safety, clinical performance and benefit-risk profile remain acceptable. Post-Market Clinical Follow-up (PMCF) is an important part of this ongoing process.
PMCF forms part of the manufacturer’s wider Post-Market Surveillance (PMS) system and involves the proactive collection and evaluation of clinical data from devices placed on the market. Its objectives include confirming continued safety and clinical performance, identifying previously unknown side effects, monitoring identified side effects and contraindications, detecting emerging risks and ensuring the continued acceptability of the device’s benefit-risk profile. PMCF also helps manufacturers assess whether developments in clinical practice, emerging scientific evidence or changes in the current state of the art affect the device’s clinical evaluation conclusions.
The nature and extent of PMCF activities should be proportionate to the device’s intended purpose, classification, novelty, associated risks and available clinical evidence. Activities may range from targeted literature reviews and analysis of clinical experience to registries or dedicated PMCF studies. Where a manufacturer considers PMCF not applicable, this must be appropriately justified and documented in accordance with EU MDR Annex XIV, Part B.
Typical PMCF Activities
Manufacturers may undertake a range of Post-Market Clinical Follow-up (PMCF) activities to collect and evaluate clinical data throughout the device lifecycle. The methods selected should be proportionate to the device’s intended purpose, associated clinical risks and identified evidence gaps, and should be defined and justified within the PMCF Plan.
|
PMCF Activity |
Purpose |
|---|---|
|
PMCF Clinical Studies |
Collect additional clinical data on device safety, clinical performance and long-term outcomes under intended conditions of use. |
|
User and Patient Surveys |
Gather structured, clinically relevant feedback from healthcare professionals or patients regarding clinical outcomes, device performance and potential side effects. |
|
Device Registries |
Analyse relevant clinical data from patient registries or healthcare databases to assess long-term safety, performance and emerging risks. |
|
Scientific Literature Reviews |
Systematically identify and evaluate newly published clinical evidence relating to the device or relevant equivalent or similar devices, where appropriate. |
|
Complaint and Vigilance Analysis |
Review relevant PMS and vigilance findings to identify emerging clinical risks, assess their implications and determine whether additional PMCF activities are necessary. |
|
Real-World Clinical Data |
Collect and evaluate clinical information from routine device use to confirm continued safety, clinical performance and benefit-risk acceptability. |
Need to Develop a Post-Market Clinical Follow-up (PMCF) Programme?
Post-Market Clinical Follow-up (PMCF) is a key component of Clinical Evaluation under the EU MDR, helping manufacturers collect ongoing clinical evidence after CE marking. Learn how to develop compliant PMCF Plans, PMCF Evaluation Reports (PMCFERs), select appropriate data collection methods and integrate PMCF with your Clinical Evaluation Report (CER), Risk Management and Post-Market Surveillance activities in our Guide to Post-Market Clinical Follow-up (PMCF).
Clinical Evaluation vs Clinical Investigation
Although closely related, Clinical Evaluation and Clinical Investigation are distinct activities under the EU Medical Device Regulation (EU MDR). Clinical evaluation is the systematic and planned process of continuously generating, collecting, analysing and assessing clinical data to verify the safety and performance, including clinical benefits, of a medical device when used as intended. A clinical investigation, by contrast, is a systematic investigation involving one or more human subjects undertaken to assess the safety or performance of a device.
Clinical investigations are not automatically required for every medical device. Depending on the device’s intended purpose, classification and available clinical evidence, manufacturers may be able to demonstrate conformity using existing clinical data, including relevant scientific literature and post-market clinical experience. However, under EU MDR Article 61(4), clinical investigations are generally required for Class III and implantable devices unless specific regulatory exceptions apply. Clinical investigations may also be necessary for other devices where existing clinical evidence is insufficient.
A clinical investigation generates clinical data that contribute to the wider clinical evaluation process; it does not replace that process. Investigation findings must be critically appraised and considered alongside other relevant clinical evidence before conclusions are documented in the Clinical Evaluation Report (CER).
Clinical Evaluation and Clinical Investigation Compared
|
Clinical Evaluation |
Clinical Investigation |
|---|---|
|
A systematic, continuous process conducted throughout the medical device lifecycle. |
A defined clinical study involving one or more human subjects to assess device safety or performance. |
|
Required for medical devices under EU MDR Article 61. |
Generally required for Class III and implantable devices under Article 61(4), subject to specified exceptions, and for other devices where necessary to establish sufficient clinical evidence. |
|
Identifies, appraises and analyses relevant clinical data to assess safety, clinical performance and benefit-risk acceptability. |
Generates clinical data through a structured investigation conducted in accordance with applicable regulatory requirements. |
|
Considers relevant scientific literature, clinical investigations, equivalent-device data where justified, PMS and PMCF findings. |
Collects clinical data according to an investigation plan, which may involve prospective or retrospective data collection depending on the study design and regulatory context. |
|
Findings and conclusions are documented in the Clinical Evaluation Report (CER). |
Findings are documented in a Clinical Investigation Report, with relevant results incorporated into the clinical evaluation. |
|
Continues throughout the device lifecycle and is updated using relevant new clinical evidence. |
Has a defined investigation period, although follow-up activities and subsequent reporting may continue after the main investigation phase. |
When Is a Clinical Investigation Required?
Whether a Clinical Investigation is required depends on the device’s classification, intended purpose, applicable EU MDR requirements and the sufficiency of available clinical evidence.
Under EU MDR Article 61(4), clinical investigations are generally required for Class III and implantable devices, unless the manufacturer can demonstrate that a specified regulatory exception applies.
For other medical devices, manufacturers should assess whether existing clinical evidence is sufficient to demonstrate conformity with the applicable General Safety and Performance Requirements (GSPRs). A clinical investigation may be necessary where:
-
The device incorporates novel technology or an innovative mechanism of action.
-
Existing clinical evidence is insufficient to demonstrate safety, clinical performance or clinical benefits.
-
Equivalence to another device cannot be adequately demonstrated or relied upon.
-
Additional clinical evidence is required to support new indications or an expanded intended purpose.
-
Significant clinical evidence gaps are identified during the clinical evaluation.
-
Additional clinical data are required to address regulatory concerns raised during conformity assessment.
For established medical devices with well-understood technologies and sufficient relevant clinical evidence, manufacturers may be able to demonstrate conformity without conducting a new clinical investigation, provided the applicable EU MDR requirements are satisfied.
Any decision not to conduct a clinical investigation should be supported by an appropriate scientific and regulatory justification, documented within the clinical evaluation and technical documentation.
Keeping Up with the Latest MDR Clinical Evaluation Guidance?
The expectations for Clinical Evaluation continue to evolve through new Medical Device Coordination Group (MDCG) guidance. Discover the latest changes affecting Clinical Evaluation Reports (CERs), equivalence, clinical evidence, PMCF and Notified Body expectations in our Clinical Evaluation Under MDR: 2025 MDCG Updates.
Common Clinical Evaluation Mistakes and How to Avoid Them
Preparing a medical device clinical evaluation under the EU MDR can be challenging, particularly for manufacturers transitioning from the Medical Devices Directive (MDD) or developing innovative medical technologies. Deficiencies in Clinical Evaluation Reports (CERs), such as insufficient clinical evidence, poorly justified equivalence or inadequate data appraisal, can lead to additional questions from Notified Bodies, requests for further evidence and delays in conformity assessment. Notified Bodies assess not only the completeness of the Clinical Evaluation Report but also the scientific validity of its methodology, the sufficiency of the supporting clinical evidence and the justification for the conclusions reached.
Many of these issues can be avoided through early planning, a well-structured Clinical Evaluation Plan (CEP) and a systematic approach to identifying, appraising and maintaining relevant clinical evidence. Understanding common clinical evaluation mistakes can help manufacturers prepare more robust documentation and address potential deficiencies before regulatory review.
Common Clinical Evaluation Pitfalls
|
Common Mistake |
How to Avoid It |
|---|---|
|
Relying on outdated clinical evidence |
Regularly review relevant scientific literature, PMS and PMCF findings, and changes in the current state of the art to ensure clinical evaluation conclusions remain valid. |
|
Poorly defined intended purpose |
Clearly establish the device’s intended purpose, indications, contraindications, intended users, target patient population and clinical claims before conducting the evaluation. |
|
Inadequate literature search strategy |
Develop a systematic, documented and reproducible literature search strategy with appropriate databases, search terms, inclusion and exclusion criteria, and search records. |
|
Insufficient critical appraisal |
Evaluate the scientific validity, methodological quality, relevance, limitations and potential bias of clinical data rather than simply summarising publications. |
|
Poorly justified equivalence |
Demonstrate technical, biological and clinical equivalence in accordance with EU MDR Annex XIV and ensure sufficient access to the data needed to support the equivalence claim. |
|
Ignoring post-market evidence |
Assess relevant complaints, vigilance information, PMS findings and PMCF clinical data when reviewing the device’s continued safety, performance and benefit-risk acceptability. |
|
Treating the CER as a one-off document |
Establish a documented process for reviewing new clinical information and updating the Clinical Evaluation Report (CER) when necessary. |
|
Poor alignment with risk management |
Ensure clinical safety findings, residual risks and benefit-risk conclusions are consistent with the device’s ISO 14971 Risk Management File. |
Preparing for Notified Body Review?
Clinical Evaluation is one of the most closely scrutinised elements of your Technical Documentation during conformity assessment. Learn how Notified Bodies assess Clinical Evaluation Reports (CERs), clinical evidence, Risk Management, Post-Market Clinical Follow-up (PMCF) and overall MDR compliance in our Guide to EU MDR Notified Bodies.
Conclusion
Medical device clinical evaluation is a fundamental requirement of the EU Medical Device Regulation (EU MDR). Manufacturers must demonstrate that their devices achieve their intended clinical benefits, meet applicable safety and performance requirements, and maintain an acceptable benefit-risk profile throughout their lifecycle. A structured Clinical Evaluation Plan (CEP), supported by sufficient clinical evidence and documented within a comprehensive Clinical Evaluation Report (CER), provides the foundation for demonstrating conformity.
Clinical evaluation must also remain current as new evidence becomes available. By integrating clinical evaluation with Risk Management, Post-Market Surveillance (PMS) and Post-Market Clinical Follow-up (PMCF), manufacturers can identify emerging risks, address evidence gaps and maintain confidence in the continued safety and clinical performance of their devices.
Need support with your medical device clinical evaluation? At Patient Guard, our regulatory specialists help manufacturers develop Clinical Evaluation Plans, conduct systematic literature reviews, prepare and update Clinical Evaluation Reports, and establish appropriate PMCF strategies. Whether you are preparing for CE marking, addressing Notified Body findings or maintaining existing technical documentation, our team can help you navigate EU MDR clinical evaluation requirements.
Frequently Asked Questions About Medical Device Clinical Evaluation
Clinical Evaluation is the systematic and ongoing process of collecting, appraising and analysing clinical data to demonstrate that a medical device is safe, performs as intended and provides an acceptable benefit-risk profile throughout its lifecycle. It is a mandatory requirement under Article 61 and Annex XIV of Regulation (EU) 2017/745 (EU MDR).
Yes. Every medical device placed on the EU market under the MDR requires a Clinical Evaluation. However, the depth and complexity of the evaluation should be proportionate to the device’s classification, intended purpose, level of innovation and associated clinical risks.
The Clinical Evaluation Plan (CEP) defines how the Clinical Evaluation will be performed, including the objectives, methodology and evidence sources. The Clinical Evaluation Report (CER) documents the completed evaluation, summarises the clinical evidence reviewed and presents the manufacturer’s conclusions regarding safety, clinical performance and benefit-risk.
No. A Clinical Investigation is only required when existing clinical evidence is insufficient to demonstrate conformity with the EU MDR. Many established devices can rely on published literature, Post-Market Surveillance (PMS), Post-Market Clinical Follow-up (PMCF) and other clinical evidence, provided it adequately supports the device’s intended purpose and clinical claims.
The Clinical Evaluation Report should be reviewed and updated whenever significant new clinical information becomes available, such as new scientific literature, PMCF findings, Post-Market Surveillance data, vigilance reports or changes to the device or its intended purpose. Regular updates form part of the manufacturer’s lifecycle obligations under the EU MDR.
Clinical evidence may include scientific literature, Clinical Investigations, equivalent device data (where appropriately justified), Post-Market Surveillance, Post-Market Clinical Follow-up, device registries, real-world clinical experience and vigilance data. Manufacturers should evaluate all relevant evidence collectively rather than relying on a single source.
PMCF is used to collect additional clinical data after a device has been placed on the market. It helps confirm the continued safety, clinical performance and benefit-risk profile of the device while identifying emerging risks or opportunities for improvement throughout its lifecycle.
Clinical Evaluation and Risk Management are closely linked. Clinical evidence is used to verify that identified risks remain acceptable when balanced against the clinical benefits of the device. Likewise, Risk Management identifies hazards that should be considered during the Clinical Evaluation process.
Notified Bodies assess whether the Clinical Evaluation has been conducted using a robust scientific methodology. They typically review the Clinical Evaluation Plan, literature search strategy, evidence appraisal, benefit-risk analysis, Clinical Evaluation Report, PMS, PMCF activities and the overall integration of Clinical Evaluation within the Technical Documentation.
Yes, provided the available literature is relevant, scientifically robust and sufficient to demonstrate the safety and clinical performance of the device. Manufacturers must critically appraise the quality of the evidence and justify why it adequately supports conformity with the EU MDR.
Clinical Evaluation is primarily governed by Article 61 and Annex XIV of Regulation (EU) 2017/745. Manufacturers should also consider relevant MDCG guidance documents, MEDDEV 2.7/1 Rev. 4 (where applicable) and harmonised standards that support the clinical evaluation process.
Yes. Patient Guard provides comprehensive Clinical Evaluation support for manufacturers of medical devices and in vitro diagnostic medical devices. Our services include Clinical Evaluation Plans (CEPs), Clinical Evaluation Reports (CERs), systematic literature reviews, clinical evidence gap assessments, PMCF planning, Clinical Investigation support and ongoing lifecycle updates to help maintain compliance with the EU MDR and UK Medical Devices Regulations.
References
This guide is based on the following legislation, international standards and official regulatory guidance relating to clinical evaluation, clinical evidence and Post-Market Clinical Follow-up under Regulation (EU) 2017/745 (MDR).
| Organisation | Reference | Why it's relevant |
|---|---|---|
| European Union | Regulation (EU) 2017/745 on Medical Devices (MDR) | Provides the legal framework for clinical evaluation under Article 61 and Annex XIV, including Clinical Evaluation Plans, Clinical Evaluation Reports, clinical evidence, equivalence, clinical investigations and Post-Market Clinical Follow-up. |
| European Commission | MEDDEV 2.7/1 Rev. 4 – Clinical Evaluation: A Guide for Manufacturers and Notified Bodies | Provides the established methodology for planning, conducting, documenting and updating clinical evaluations, including literature searching, appraisal of clinical data, analysis of evidence and preparation of Clinical Evaluation Reports. Although published under the former Directives, relevant sections continue to be referenced under the MDR where consistent with current legislation. |
| Medical Device Coordination Group (MDCG) | MDCG 2020-6 – Guidance on Sufficient Clinical Evidence for Legacy Devices | Explains how manufacturers should determine and justify a sufficient level of clinical evidence, including the use of pre-market and post-market clinical data to demonstrate conformity with the MDR. |
| Medical Device Coordination Group (MDCG) | MDCG 2020-5 – Guidance on Clinical Evaluation and Equivalence | Provides detailed guidance on demonstrating technical, biological and clinical equivalence and documenting the comparison with an equivalent device within the Clinical Evaluation Report. |
| Medical Device Coordination Group (MDCG) | MDCG 2020-7 – Post-Market Clinical Follow-up Plan Template | Provides an official template and guidance for planning Post-Market Clinical Follow-up activities to confirm the continued safety, clinical performance and benefit-risk acceptability of medical devices after they have been placed on the market. |
| Medical Device Coordination Group (MDCG) | MDCG 2020-8 – Post-Market Clinical Follow-up Evaluation Report Template | Provides an official structure for documenting PMCF findings and explains how those findings should feed back into the Clinical Evaluation Report, risk management documentation and post-market surveillance activities. |
| International Organization for Standardization (ISO) | ISO 14155:2026 – Clinical Investigation of Medical Devices for Human Subjects – Good Clinical Practice | Defines internationally recognised Good Clinical Practice requirements for designing, conducting, recording and reporting clinical investigations used to generate clinical evidence for medical devices. |
Clinical evaluation requirements continue to evolve through legislation, recognised standards and regulatory guidance. Manufacturers should always consult the latest published legislation, international standards and official guidance when planning clinical evaluations, assessing clinical evidence, conducting clinical investigations and maintaining Clinical Evaluation Reports throughout the medical device lifecycle.
David Small BSc (Hons), MSc, MTOPRA
Reviewed by
David Small, BSc (Hons), MSc, MTOPRA
Founder & CEO |
20+ years in medical device regulatory affairs, MDR/IVDR compliance and quality systems.
Patient Guards Recent Posts

FDA QMSR and ISO 13485: What Medical Device Manufacturers Need to Know in 2026
FDA’s Quality Management System Regulation (QMSR) is now in effect. This guide explains how QMSR incorporates ISO 13485:2016, what FDA-specific requirements remain, how FDA inspections have changed and what medical device manufacturers need to do to maintain US compliance.

MHRA Confirms Indefinite Recognition of CE-Marked Medical Devices in Great Britain
The MHRA has confirmed plans to recognise CE-marked medical devices indefinitely in Great Britain, removing the planned 2030 deadline for qualifying EU MDR and IVDR devices. Discover what this significant regulatory announcement means for manufacturers, UKCA marking, UK Responsible Person requirements and future access to the UK medical device market.

FDA Medical Device Classification: Class I, Class II and Class III Explained
Understand FDA medical device classification and the differences between Class I, Class II and Class III devices. Learn how to identify your FDA product code, regulatory controls, 510(k) exemptions and the appropriate pathway to the US market.
Patient Guards Related Services
Patient Guards Regulatory Tools
Need Training?
Do you need training on Quality Management Systems or EU MDR/ EU IVDR? then check out our training courses.